182 related articles for article (PubMed ID: 23536726)
21. Deregulated Stat3 signaling dissociates pulmonary inflammation from emphysema in gp130 mutant mice.
Ruwanpura SM; McLeod L; Miller A; Jones J; Vlahos R; Ramm G; Longano A; Bardin PG; Bozinovski S; Anderson GP; Jenkins BJ
Am J Physiol Lung Cell Mol Physiol; 2012 Apr; 302(7):L627-39. PubMed ID: 22268122
[TBL] [Abstract][Full Text] [Related]
22. A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130.
Hong SS; Choi JH; Lee SY; Park YH; Park KY; Lee JY; Kim J; Gajulapati V; Goo JI; Singh S; Lee K; Kim YK; Im SH; Ahn SH; Rose-John S; Heo TH; Choi Y
J Immunol; 2015 Jul; 195(1):237-45. PubMed ID: 26026064
[TBL] [Abstract][Full Text] [Related]
23. Bazedoxifene, a GP130 Inhibitor, Modulates EMT Signaling and Exhibits Antitumor Effects in HPV-Positive Cervical Cancer.
Kim L; Park SA; Park H; Kim H; Heo TH
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445405
[TBL] [Abstract][Full Text] [Related]
24. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
Gritsina G; Xiao F; O'Brien SW; Gabbasov R; Maglaty MA; Xu RH; Thapa RJ; Zhou Y; Nicolas E; Litwin S; Balachandran S; Sigal LJ; Huszar D; Connolly DC
Mol Cancer Ther; 2015 Apr; 14(4):1035-47. PubMed ID: 25646015
[TBL] [Abstract][Full Text] [Related]
25. Cytokine signalling via gp130 in gastric cancer.
Howlett M; Menheniott TR; Judd LM; Giraud AS
Biochim Biophys Acta; 2009 Nov; 1793(11):1623-33. PubMed ID: 19665497
[TBL] [Abstract][Full Text] [Related]
26. Discovery of bazedoxifene analogues targeting glycoprotein 130.
Song D; Yu W; Ren Y; Zhu J; Wan C; Cai G; Guo J; Zhang W; Kong L
Eur J Med Chem; 2020 Aug; 199():112375. PubMed ID: 32388278
[TBL] [Abstract][Full Text] [Related]
27. Activating the interleukin-6-Gp130-STAT3 pathway ameliorates ventricular electrical stability in myocardial infarction rats by modulating neurotransmitters in the paraventricular nucleus.
Gao M; Yin D; Chen J; Qu X
BMC Cardiovasc Disord; 2020 Feb; 20(1):60. PubMed ID: 32024466
[TBL] [Abstract][Full Text] [Related]
28. IL-6 induces MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines.
Mejías-Luque R; Peiró S; Vincent A; Van Seuningen I; de Bolós C
Biochim Biophys Acta; 2008 Oct; 1783(10):1728-36. PubMed ID: 18573283
[TBL] [Abstract][Full Text] [Related]
29. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.
Kim MJ; Nam HJ; Kim HP; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Cancer Lett; 2013 Jul; 335(1):145-52. PubMed ID: 23402820
[TBL] [Abstract][Full Text] [Related]
30. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.
Chen X; Tian J; Su GH; Lin J
Curr Cancer Drug Targets; 2019; 19(5):417-427. PubMed ID: 29714141
[TBL] [Abstract][Full Text] [Related]
31. Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells.
Wu X; Xiao H; Wang R; Liu L; Li C; Lin J
Curr Cancer Drug Targets; 2016; 16(7):631-8. PubMed ID: 26373715
[TBL] [Abstract][Full Text] [Related]
32. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
33. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.
Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633
[TBL] [Abstract][Full Text] [Related]
34. Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy.
Wei J; Ma L; Lai YH; Zhang R; Li H; Li C; Lin J
J Exp Clin Cancer Res; 2019 Feb; 38(1):63. PubMed ID: 30736824
[TBL] [Abstract][Full Text] [Related]
35. Coinhibition of S1PR1 and GP130 by siRNA-loaded alginate-conjugated trimethyl chitosan nanoparticles robustly blocks development of cancer cells.
Rostami N; Nikkhoo A; Khazaei-Poul Y; Farhadi S; Sadat Haeri M; Moghadaszadeh Ardebili S; Aghaei Vanda N; Atyabi F; Namdar A; Baghaei M; Haghnavaz N; Kazemi T; Yousefi M; Ghalamfarsa G; Sabz G; Jadidi-Niaragh F
J Cell Physiol; 2020 Dec; 235(12):9702-9717. PubMed ID: 32424937
[TBL] [Abstract][Full Text] [Related]
36. Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells.
Shi Y; Zhou W; Cheng L; Chen C; Huang Z; Fang X; Wu Q; He Z; Xu S; Lathia JD; Ping Y; Rich JN; Bian XW; Bao S
Cell Death Differ; 2017 Jan; 24(1):167-180. PubMed ID: 27740621
[TBL] [Abstract][Full Text] [Related]
37. Repurposing the selective estrogen receptor modulator
Thilakasiri P; Huynh J; Poh AR; Tan CW; Nero TL; Tran K; Parslow AC; Afshar-Sterle S; Baloyan D; Hannan NJ; Buchert M; Scott AM; Griffin MD; Hollande F; Parker MW; Putoczki TL; Ernst M; Chand AL
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30885958
[TBL] [Abstract][Full Text] [Related]
38. Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver.
Graf D; Kohlmann C; Haselow K; Gehrmann T; Bode JG; Häussinger D
Hepatology; 2006 Nov; 44(5):1206-17. PubMed ID: 17058237
[TBL] [Abstract][Full Text] [Related]
39. IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells.
Carbotti G; Nikpoor AR; Vacca P; Gangemi R; Giordano C; Campelli F; Ferrini S; Fabbi M
J Exp Clin Cancer Res; 2017 Oct; 36(1):140. PubMed ID: 29020964
[TBL] [Abstract][Full Text] [Related]
40. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
